iOMEDICO

What iOMEDICO does

iOMEDICO AG is a Freiburg, Germany-based clinical research organization founded in 1993 that specializes in oncology and hematology clinical research. The company runs full-service Phase I–IV clinical trials, investigator-initiated non-interventional studies (NIS), and prospective tumor registries for pharmaceutical sponsors, academic study groups, and specialist associations. Its core research infrastructure is a proprietary network of approximately 150 partner study centers that collect detailed clinical data from over 6,000 new oncology patients annually, supported by a wholly-owned subsidiary (iOMEDICO SMO GmbH) that coordinates patient-reported outcome surveys, dispatching over 21,500 questionnaires per year with reported response rates of 70–90%.

The company's technology stack is anchored by iOstudy office edc, a web-based Electronic Data Capture system developed in-house since 1993 and continuously updated for regulatory compliance (CDISC, FDA 21 CFR Part 11, EU GMP Annex 11). It is complemented by the TRIALS patient recruitment platform, the Studien- und Registerportal for study and registry management, and the PRO Patient survey tool. More recently, iOMEDICO has layered AI capabilities onto this stack through two government-funded projects: NextGenTMF (BMBFTR-funded, completed April 2025), which uses OCR, NLP, and large language models for eTMF document digitization, and NIO (launched May 2024), a federated learning initiative for cross-institutional pattern recognition in cancer registries.

The business operates on a professional services model, with quote-based contracts to enterprise pharmaceutical clients and academic research institutions. Marketing is conducted almost entirely through peer-reviewed scientific publications, dedicated scientific symposia (e.g., the 14th Scientific Study Symposium in Frankfurt, the Symposium for Hematologic Malignancies in Munich, and the Real World Data conference in Cologne), and direct enterprise relationships rather than broad-based demand generation. The company is privately held under German AG corporate form, with management comprising Michael Pröschel, Sybille Marschner, and Dr. Norbert Marschner on the Vorstand, and Thomas Maisch chairing the Supervisory Board; no external venture or private equity investment is evidenced.

Name

iOMEDICO

Legal name

iOMEDICO AG

Website

https://iomedico.com

Company type

Private

Founded year

1993

Operating status

Operating

Short description

iOMEDICO AG is a privately held German clinical research organization specializing in oncology and hematology clinical trials, non-interventional studies, and prospective tumor registries. It serves pharmaceutical sponsors and academic study groups through a proprietary EDC platform and a network of approximately 150 study centers.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Oncology clinical research
• Clinical trial services
• Electronic data capture
• Real-world evidence
• Patient-reported outcomes

Headquarters

HQ city

Freiburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services (Full-Service CRO): Full-service Clinical Research Organization offering all clinical research services from conception to publication, including clinical trials Phase I-IV and prospective tumor registries.
2. Non-Interventional Studies and Registries: Investigator-initiated prospective non-interventional studies evaluating real-world effectiveness, safety, and treatment patterns. Generates real-world evidence for pharmaceutical partners.
3. Patient Survey Services: Coordinates patient surveys including conception, validated questionnaire selection, questionnaire development, questionnaire management, evaluation, and publication. Sends over 21,500 questionnaires per year with 70-90% response rates.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

iOMEDICO is a specialized oncology and hematology Clinical Research Organization (CRO) that designs, manages, and conducts clinical trials (Phase I-IV), non-interventional studies, tumor registries, and patient-reported outcome surveys. The company operates an oncology network of approximately 150 study centers, collecting detailed clinical data from over 6,000 new oncology patients annually, supported by proprietary digital platforms for electronic data capture (iOstudy office edc), patient recruitment (TRIALS), study/registry portals, and digital patient surveys (PRO Patient).

Product overview

iOMEDICO is an oncology-focused Clinical Research Organization (CRO) offering a suite of proprietary digital solutions for clinical research. The core platform is the iOstudy office edc system, a web-based Electronic Data Capture (EDC) system developed since 1993. This core system is complemented by TRIALS (patient recruitment platform), the Studien- und Registerportal (Study and Registry Portal), and PRO Patient (digital patient survey tool). These products are tightly integrated: the EDC serves as the central data capture engine, the Study Portal provides project management and direct access to the EDC, TRIALS supports patient recruitment, and PRO Patient enables patient-reported outcomes collection. All solutions share digital, paperless infrastructure aligned with iOMEDICO's 1993 vision of 'paperless clinical trials.'

Differentiator

Problem solved

Functional benefit

Brands

• TRIALS: Platform for efficient patient enrollment in studies - internet tool providing overview of all study-relevant information adapted for recruiting study projects at centers
• Studienportal
• Registerportal
• iOstudy office edc

Products and services

• Full-Service Clinical Research (CRO) Services Full-service Clinical Research Organization offering all clinical research services from conception to publication, including Phase I-IV clinical trials for pharmaceutical companies, study groups, and medical associations.
• Non-Interventional Studies (NIS) and Tumor Registries Investigator-initiated prospective non-interventional studies evaluating real-world effectiveness, safety, and treatment patterns; generates real-world evidence for pharmaceutical partners through registries.
• Patient Survey Services Coordinates patient surveys including conception, validated questionnaire selection, questionnaire development, questionnaire management, evaluation, and publication for clinical trials and health care research.
• iOstudy office edc (Electronic Data Capture System) Web-based Electronic Data Capture system for paperless clinical trial data documentation featuring automatic plausibility and completeness checks, CDISC compliance, FDA 21 CFR Part 11 compliance, EU GMP Annex 11 compliance, E2B Export, SAE Reporting, and Risk Based Monitoring capabilities.
• TRIALS Internet platform for efficient patient recruitment in clinical studies that presents all relevant study information individually adapted for recruiting study projects at a center, enabling quick identification of appropriate studies for patients with just a few clicks.
• Studien- und Registerportal (Study and Registry Portal) Online portal providing comprehensive project information for studies and registries, including presentations, study results, publications, visually supported identification of open studies, daily status reports, recruitment charts, important study documents, and direct access to the EDC system.

Quantifiable outcome

• 21,500+ patient questionnaires sent per year with 70-90% response rates
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Oncopeptides ABcoreStrategic or Co-development Partner · 16 March 2026MARINA study collaboration - an investigator-initiated prospective non-interventional study evaluating the real-world effectiveness, safety, and treatment patterns of Pepaxti (melflufen) in combination with dexamethasone for patients with relapsed, refractory multiple myeloma in Germany. Study will observe 50 patients across approximately 25 sites with first patient enrollment expected in Q2 2026.
• Furtwangen University (HFU) - IDACUS InstitutecoreStrategic or Co-development Partner · 1 May 2024Project 'Development of an AI-supported information system for oncologists' (NIO) funded by German Federal Ministry of Education and Research (BMFTR). Aims to develop AI system enabling research oncologists to analyze cancer registries across institutions using federated learning approach - AI models trained decentrally on real-world data from different institutions while maintaining patient data protection.
• University of Würzburg, Chair of Artificial Intelligence and Knowledge SystemscoreStrategic or Co-development Partner · 1 March 2022NextGenTMF project collaboration for regulatory compliant document management in Trial Master File through artificial intelligence. Funded by Federal Ministry of Education and Research (BMFTR) in KMU Innovativ ICT programme lasting 30 months.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Theradex: Dedicated oncology CRO offering clinical trial management and oncology-focused services. Highly comparable therapeutic focus and CRO model.
• Medpace: Mid-size US-headquartered CRO with a strong oncology franchise and full-service Phase I-IV capabilities. Highly comparable in its therapeutic specialization and full-service model, though substantially larger in scale and global reach.
• Worldwide Clinical Trials: Mid-size specialty CRO with deep oncology and hematology expertise offering full-service clinical development. Comparable positioning as a therapeutically focused alternative to broad-line CROs.
• Ergomed: Specialty CRO with strong oncology and rare disease focus and meaningful European footprint. Direct comparable in therapeutic specialization and geographic overlap with iOMEDICO's DACH base.
• Clinipace Worldwide: Mid-size oncology-focused CRO delivering full-service clinical trial services to emerging and mid-market biopharma. Comparable therapeutic specialization and full-service CRO model.
• Precision for Medicine: Specialty CRO focused on oncology and rare disease with biomarker-driven trial capabilities. Direct comparable in therapeutic specialization and investigator/site-network approach.

Broad incumbents

• Parexel: Global full-service CRO with significant oncology practice and broad biopharmaceutical customer base. Competes for the same oncology sponsors as iOMEDICO but at substantially greater scale and geographic breadth.
• IQVIA: Largest global CRO with leading real-world evidence and oncology data assets. Competes with iOMEDICO for oncology trials and RWE contracts but serves a much wider portfolio of therapeutic areas and customers.

Emerging players

• Flatiron Health: Oncology-focused real-world data and clinical research platform (Roche subsidiary). Comparable in oncology data network and registry approach, though operating a software/data model rather than full-service CRO.
• COTA Healthcare: Oncology real-world evidence and data analytics company serving pharma and providers. Adjacent comparator in oncology-specific data assets that increasingly substitute for some registry CRO work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/iomedico

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iOMEDICO